LUCD (Lucid Diagnostics) Debt-to-Asset : 0.58 (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Lucid Diagnostics Debt-to-Asset?

Lucid Diagnostics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $11.06 Mil. Lucid Diagnostics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $2.01 Mil. Lucid Diagnostics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was $22.60 Mil. Lucid Diagnostics's debt to asset for the quarter that ended in Sep. 2024 was 0.58.

Lucid Diagnostics Debt-to-Asset Historical Data

The historical data trend for Lucid Diagnostics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lucid Diagnostics Debt-to-Asset Chart

Lucid Diagnostics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

0.06

0.56

Lucid Diagnostics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial														0.48	0.56	0.44	0.42	0.58

Competitive Comparison of Lucid Diagnostics's Debt-to-Asset

For the Medical Devices subindustry, Lucid Diagnostics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lucid Diagnostics's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lucid Diagnostics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Lucid Diagnostics's Debt-to-Asset falls into.

Lucid Diagnostics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Lucid Diagnostics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(15.056	+	0.199)	/	27.27
	=	0.56

Lucid Diagnostics's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(11.055	+	2.011)	/	22.598
	=	0.58

Lucid Diagnostics (NAS:LUCD) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Lucid Diagnostics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Lucid Diagnostics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Lucid Diagnostics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lucid Diagnostics Inc (NAS:LUCD) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

360 Madison Avenue, 25th Floor, New York, NY, USA, 10017

Website

https://www.luciddx.com

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.

Executives

Stanley Lapidus	director	101 HARTWELL AVE., LEXINGTON MA 02421
Debra White	director	C/O PAVMED INC., ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Michael Adam Gordon	officer: General Counsel	ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Shaun O'neil	officer: Chief Operating Officer	ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Pavmed Inc.	10 percent owner	360 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10017
Lishan Aklog	director, officer: Chief Executive Officer	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171
Dennis M Mcgrath	officer: Chief Financial Officer	C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Ronald M Sparks	director	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
James L Cox	director	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Aster Angagaw	director	150 PEABODY PLACE, MEMPHIS TN 38103
Jacque J Sokolov	director
David F Wurtman	officer: Chief Medical Officer	ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165